Skip to main content
. 2016 Oct 11;187(2):213–224. doi: 10.1111/cei.12868

Figure 1.

Figure 1

Protocol for induction of muscarinic acetylcholine receptor (M3R)‐induced murine autoimmune sialadenitis (MIS) and treatment with A213 for MIS. (a) M3R–/– mice were immunized with M3R peptide mixture on day 0. On day 10, each mouse was immunized with intradermal injection of the same mixture. On day 20, splenocytes were isolated from immunized M3R–/– mice and inoculated into recombination‐activating gene 1 (Rag‐1)–/– mice. At day 45 after the inoculation, Rag1–/– recipient mice (M3R–/–→Rag‐1–/–) were analysed. (b) Structure of A213 (kindly provided by Daiichi‐Sankyo Company). (c) A213 was dissolved in phosphate‐buffered saline (PBS) and administered orally at 300 mg/kg body weight every 3 days. The administration was started at day 1 after first immunization in immunized M3R–/– mice (protocol A, pretransfer treatment) and at day 7 after inoculation in M3R–/–→Rag‐1–/– mice (protocol B, post‐transfer treatment), and continued until days 19 and 42, respectively.